149 related articles for article (PubMed ID: 27279153)
1. The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.
Gmeiner WH; Debinski W; Milligan C; Caudell D; Pardee TS
Future Oncol; 2016 Sep; 12(17):2009-20. PubMed ID: 27279153
[TBL] [Abstract][Full Text] [Related]
2. The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2.
Gmeiner WH; Boyacioglu O; Stuart CH; Jennings-Gee J; Balaji KC
Prostate; 2015 Mar; 75(4):360-9. PubMed ID: 25408502
[TBL] [Abstract][Full Text] [Related]
3. Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition.
Mani C; Pai S; Papke CM; Palle K; Gmeiner WH
Neoplasia; 2018 Dec; 20(12):1236-1245. PubMed ID: 30439567
[TBL] [Abstract][Full Text] [Related]
4. All-Atom Molecular Dynamics Reveals Mechanism of Zinc Complexation with Therapeutic F10.
Melvin RL; Gmeiner WH; Salsbury FR
J Phys Chem B; 2016 Oct; 120(39):10269-10279. PubMed ID: 27606431
[TBL] [Abstract][Full Text] [Related]
5. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
[TBL] [Abstract][Full Text] [Related]
6. Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors.
Gmeiner WH; Lema-Tome C; Gibo D; Jennings-Gee J; Milligan C; Debinski W
J Neurooncol; 2014 Feb; 116(3):447-54. PubMed ID: 24346635
[TBL] [Abstract][Full Text] [Related]
7. Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.
Gmeiner WH; Jennings-Gee J; Stuart CH; Pardee TS
Leuk Res; 2015 Feb; 39(2):229-35. PubMed ID: 25510486
[TBL] [Abstract][Full Text] [Related]
8. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with
Haber AO; Jain A; Mani C; Nevler A; Agostini LC; Golan T; Palle K; Yeo CJ; Gmeiner WH; Brody JR
Mol Cancer Res; 2021 Apr; 19(4):565-572. PubMed ID: 33593942
[TBL] [Abstract][Full Text] [Related]
9. F10 Inhibits Growth of PC3 Xenografts and Enhances the Effects of Radiation Therapy.
Gmeiner WH; Willingham MC; Bourland JD; Hatcher HC; Smith TL; D'Agostino RB; Blackstock W
J Clin Oncol Res; 2014; 2(4):. PubMed ID: 26020060
[TBL] [Abstract][Full Text] [Related]
10. Acyclic analogues of 5-fluoro-dUMP and 5-fluoro-2'-deoxyuridine: synthesis and inhibition of thymidylate synthase and tumour cell growth.
Felczak K; Gołos B; Dzik JM; Rode W; Bretner M; Shugar D; Kulikowski T
Acta Biochim Pol; 1998; 45(1):75-82. PubMed ID: 9701498
[TBL] [Abstract][Full Text] [Related]
11. Combined modulation by leucovorin and alpha-2a interferon of fluoropyrimidine mediated growth inhibition.
Sinnige HA; Timmer-Bosscha H; Peters GF; De Vries EG; Mulder NH
Anticancer Res; 1993; 13(5A):1335-40. PubMed ID: 8239504
[TBL] [Abstract][Full Text] [Related]
12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
Schott S; Niessner H; Sinnberg T; Venturelli S; Berger A; Ikenberg K; Villanueva J; Meier F; Garbe C; Busch C
Int J Cancer; 2012 Nov; 131(9):2165-74. PubMed ID: 22323315
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine Modulation of the Anti-Tumor Immune Response-Prospects for Improved Colorectal Cancer Treatment.
Gmeiner WH
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32575843
[TBL] [Abstract][Full Text] [Related]
15. [Inhibition of thymidylate synthase in chemotherapy].
Rode W
Postepy Biochem; 1996; 42(2):133-40. PubMed ID: 8805186
[No Abstract] [Full Text] [Related]
16. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
17. Sulfonyl-containing nucleoside phosphotriesters and phosphoramidates as novel anticancer prodrugs of 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP).
Sun YW; Chen KM; Kwon CH
Mol Pharm; 2006; 3(2):161-73. PubMed ID: 16579645
[TBL] [Abstract][Full Text] [Related]
18. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of thymidylate synthase-catalyzed reaction and interaction of the enzyme with 2- and/or 4-substituted analogues of dUMP and 5-fluoro-dUMP.
Rode W; Leś A
Acta Biochim Pol; 1996; 43(1):133-42. PubMed ID: 8790719
[TBL] [Abstract][Full Text] [Related]
20. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Johnston PG; Drake JC; Trepel J; Allegra CJ
Cancer Res; 1992 Aug; 52(16):4306-12. PubMed ID: 1643628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
